NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01118234,Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia),https://clinicaltrials.gov/study/NCT01118234,,COMPLETED,"The purpose of the study is to evaluate the ability of Rituximab maintenance therapy to prolong progression free survival in patients with chronic lymphocytic leukemia, who responded to a Rituximab induction therapy.",NO,Chronic Lymphocytic Leukemia,DRUG: Rituximab,"progression free survival, Clinical PFS is defined as the period from randomization until disease progression according to the NCI criteria or death due to the underlying disease., 48 months","MRD (minimal residual disease) progression free survival, Minimal residual disease progression-free survival is defined as the period from randomization until increase of MRD levels in peripheral blood above 10-3 or, if above 10-3 before, increase of one common logarithm., 48 months|conversion rate to MRD negative, 48 months|median MRD levels, 48 months|conversation rate to CR, 48 months|effect of MRD levels on clinical PFS and OS, 48 months|event free survival, 48 months|time to next treatment, 48 months|overall survival, 48 months|Safety of Rituximab maintenance treatment in patients with CLL, All grades of infections and G3/4 other clinical adverse events will be documented using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, 48 months|benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q), IgVH mutation status, ZAP 70 and CD38 expression, 48 months",,Arbeitsgemeinschaft medikamentoese Tumortherapie,Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",PHASE3,256,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Mabtenance,2009-12,2018-02,2019-07,2010-05-06,,2020-01-09,"Landesklinikum Krems, Hämato-onkologisches Service, Krems, Niederösterreich, 3500, Austria|AKH Linz, Department für Innere Medizin 3, Linz, Oberösterreich, 4021, Austria|Landeskrankenhaus Steyr, Innere Medizin, Hämatologie, Onkologie, Steyr, Oberösterreich, 4400, Austria|Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV, Wels, Oberösterreich, 4600, Austria|A.ö. Bezirkskrankenhaus Hall in Tirol, Innere Medizin / Hämato - Onkologie, Hall In Tirol, Tirol, 6060, Austria|Universitätsklinik Innsbruck, Innere MEdizin IV / Hämato-Onkologie, Innsbruck, Tirol, 6020, Austria|A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie, Kufstein, Tirol, 6330, Austria|LKH Feldkirch, Interne E, Feldkirch, Vorarlberg, 6807, Austria|Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin, Salzburg, 5020, Austria|AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie, Wien, 1090, Austria|Hanusch Krankenhaus, 3. Med. Abtlg., Wien, 1140, Austria|FN Brno, Brno, 62588, Czechia|FN Hradec Kralove, Hradec Kralove, 500 05, Czechia|FN Olomouc, Olomouc, Czechia|FN Kralovske Vinohrady, Praha, 10034, Czechia|VFN Praha 2, Praha, 12808, Czechia|F.D. Rossevelt hospital, Banská Bystrica, 97517, Slovakia|Narodny onkologicky ustav, Bratislava, 83310, Slovakia|FNsP sv. Cyrila a Metoda, Bratislava, 85107, Slovakia|FNsP L.Pasteura, Kosice, 04190, Slovakia|Martinska fakultna nemocnica, Martin, 03659, Slovakia|FNsP J.A. Reimana, Presov, 08181, Slovakia",
